3 terminated, 2 completed, 2 recruiting, 1 active not recruiting. 6 Phase 1, 4 Phase 2, 1 Not applicable, 1 Phase 3.
Follow CTCL: new trials by email Literature Review of CTCL trials Research Report on CTCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma FG-M131 - PTCL, TRBC1 ADC | Phase 1 / Phase 2 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 110 | 2026-08-30 | 2026-09-02 |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL PTX-100 - CTCL | Phase 2 | Recruiting | Prescient Therapeutics, Ltd. | 115 | 2025-03-28 | 2026-09-09 |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL Hypericin, Placebo - CTCL/ Mycosis Fungoides, CTCL | Phase 3 | Terminated | Soligenix | 70 | 2025-01-07 | 2026-07-13 |
| Ritlecitinib in CTCL Ritlecitinib - CTCL, Mycosis Fungoides | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2023-05-17 | 2025-07-18 |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Pembrolizumab, Pralatrexate, Decitabine - PTCL, CTCL | Phase 1 | Active not recruiting | University of Virginia | 37 | 2022-02-02 | 2026-04-07 |
| StrataCTX® as a Steroid Sparing Device StrataCTX® gel - CTCL | Not applicable | Recruiting | Columbia University | 70 | 2021-07-07 | 2026-09-11 |
| A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) ABT-199 (venetoclax) - CTCL | Phase 1 | Completed | Yale University | 4 | 2020-01-15 | 2021-06-25 |
| A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL BNZ132-1-40 - LGL Leukemia, CTCL | Phase 1 / Phase 2 | Completed | Bioniz Therapeutics | 50 | 2018-04-01 | 2021-05-25 |
| Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL Volasertib, Romidepsin - PTCL, CTCL | Phase 1 | Withdrawn | Anne Beaven, MD | 2016-11-01 | 2016-12-01 | |
| A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors MEDI9197, durvalumab - Solid Tumors, CTCL | Phase 1 | Terminated | MedImmune LLC | 53 | 2015-11-04 | 2018-12-19 |
Mycosis Fungoides (3) · Lymphoma, T-Cell (2) · Lymphoma, T-Cell, Cutaneous (2) · Sezary Syndrome (2) · Leukemia, Large Granular Lymphocytic (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Recurrence (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphoma (4) · Lymphoma, Non-Hodgkin (3) · Lymphoma, T-Cell (2) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, T-Cell (1)
10-propargyl-10-deazaaminopterin (1) · BI 6727 (1) · Decitabine (1) · MEDI9197 (1) · durvalumab (1) · hypericin (1) · pembrolizumab (1) · romidepsin (1) · venetoclax (1)
Anne Beaven, MD (1) · Bioniz Therapeutics (1) · Columbia University (1) · FutureGen Biopharmaceutical (Beijing) Co., Ltd (1) · Icahn School of Medicine at Mount Sinai (1) · MedImmune LLC (1) · Prescient Therapeutics, Ltd. (1) · Soligenix (1) · University of Virginia (1) · Yale University (1)
United States (8) · France (2) · Australia (1) · Canada (1) · China (1) · Italy (1)
Enrica Marchi, MD, PhD (1) · Jonathan Brammer, MD, PhD (1) · Larisa J. Geskin, MD (1) · Michael Girardi, MD, FAAD (1) · Owen O'Connor, MD, PhD (1) · Patrick Brunner, MD (1)